What price range applied to the AQST insider share sale?

The CEO’s 8,257-share sale in Aquestive Therapeutics occurred at prices between $4.17 and $4.64 per share. The filing reports a weighted average sale price of $4.2889, and notes the company can provide detailed breakdowns of shares sold at each price upon request.

Aquestive Therapeutics (AQST) CEO sells 8,257 shares in open market

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 8,257 shares of Common Stock. The weighted average sale price was $4.2889 per share, with individual trades ranging from $4.17 to $4.64. After this transaction, he directly holds 660,574 shares.

Insider Trade Summary 10b5-1

Net Seller: 8,257 shares ($35,413)

Net Sell 1 txn

Insider Barber Daniel

Role President and CEO

Sold 8,257 shs ($35K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,257	$4.2889	$35K

Holdings After Transaction: Common Stock — 660,574 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 8,257 shares Weighted average sale price: $4.2889 per share Sale price range: $4.17–$4.64 per share +1 more

4 metrics

Shares sold 8,257 shares Open-market sale of Common Stock

Weighted average sale price $4.2889 per share Common Stock sale on 2026-05-15

Sale price range $4.17–$4.64 per share Individual trade prices within reported transaction

Shares owned after transaction 660,574 shares Direct ownership by CEO following sale

Key Terms

open-market sale, weighted average price, Form 4, non-derivative

4 terms

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The weighted average price per share was $4.2889."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 regulatory

"This sale was disclosed in a Form 4 insider trading report"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"transaction_type: non-derivative"

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 02:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barber Daniel

(Last)

(First)

(Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN

NEW JERSEY

07059

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/15/2026		S		8,257	D	$4.2889⁽¹⁾	660,574	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported transaction involves sale transactions from $4.17 to $4.64 per share. The weighted average price per share was $4.2889. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Aquestive Therapeutics (AQST) disclose?

Aquestive Therapeutics reported that President and CEO Daniel Barber sold 8,257 shares of Common Stock in an open-market transaction. This sale was disclosed in a Form 4 insider trading report filed with regulators for transparency on executive share movements.

At what price did the Aquestive Therapeutics CEO sell AQST shares?

Daniel Barber sold 8,257 Aquestive Therapeutics shares at a weighted average price of $4.2889. Individual trade prices ranged from $4.17 to $4.64 per share, reflecting multiple executions aggregated into a single reported transaction total.

How many Aquestive Therapeutics shares does the CEO hold after the sale?

After the reported sale, Aquestive Therapeutics President and CEO Daniel Barber directly holds 660,574 shares of Common Stock. This figure reflects his remaining direct ownership position following the 8,257-share open-market disposition reported in the Form 4 filing.

What does the Form 4 for Aquestive Therapeutics (AQST) represent?

The Form 4 shows an open-market sale of 8,257 Aquestive Therapeutics shares by President and CEO Daniel Barber. It details the transaction date, share amount, price range, weighted average price, and his direct share ownership after the sale for regulatory disclosure purposes.